{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:38:35Z","timestamp":1793986715424,"version":"4.8.0"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"unspecified","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2026,6,24]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"\n Introduction<\/jats:title>\n \n The dysregulation of both reduced (IL-33\n red<\/jats:sup>\n ) and oxidised (IL-33\n ox<\/jats:sup>\n ) interleukin (IL)-33 has been implicated in chronic obstructive pulmonary disease (COPD) inflammation and remodelling processes. Tozorakimab, an anti-IL-33 monoclonal antibody, inhibits both IL-33\n red<\/jats:sup>\n and IL-33\n ox<\/jats:sup>\n activity.\n <\/jats:p>\n <\/jats:sec>\n \n Methods and analysis<\/jats:title>\n \n The tozorakimab LUNA programme comprises four ongoing, multicentre, randomised, double-blind, parallel-group, placebo-controlled, phase III studies evaluating the efficacy and safety of tozorakimab in participants with symptomatic COPD and a history of exacerbations receiving optimised inhaled therapy. In OBERON (\n NCT05166889<\/jats:ext-link>\n ) and TITANIA (\n NCT05158387<\/jats:ext-link>\n ), 1132 and 1172 participants, respectively, were randomised to receive tozorakimab 300\u2009mg every 4 or 8\u2009weeks or placebo for 52\u2009weeks. In MIRANDA (\n NCT06040086<\/jats:ext-link>\n ), 1454 participants were randomised 3:2 to tozorakimab 300\u2009mg every 2\u2009weeks or placebo for \u226552\u2009weeks. In PROSPERO (\n NCT05742802<\/jats:ext-link>\n ), participants who completed treatment with tozorakimab in OBERON or TITANIA will continue treatment for an additional 28\u2009weeks or 52\u2009weeks; participants recruited from the placebo arm will be re-randomised 1:1 to tozorakimab or placebo. The primary endpoint in OBERON, TITANIA and MIRANDA is the annualised rate of moderate-to-severe COPD exacerbations; the primary endpoint in PROSPERO is the annualised rate of severe COPD exacerbations. For all studies, the primary endpoint will be first assessed in former smokers, then in current and former smokers. Secondary key endpoints include measures of lung function, respiratory symptoms, health status and safety. The tozorakimab LUNA programme is assessing the efficacy and safety of tozorakimab in participants with COPD. It is the largest pivotal programme of any biologic therapy in COPD to date.\n <\/jats:p>\n <\/jats:sec>\n \n Ethics and dissemination<\/jats:title>\n The protocols were approved by independent ethics committees and institutional review boards. Results of the studies will be submitted to the EU Clinical Trials Information System within a year from the global end of trial data in all participating countries and will be published or presented at scientific meetings.<\/jats:p>\n <\/jats:sec>\n \n Trial registration number<\/jats:title>\n \n OBERON:\n NCT05166889<\/jats:ext-link>\n ; TITANIA:\n NCT05158387<\/jats:ext-link>\n ; MIRANDA:\n NCT06040086<\/jats:ext-link>\n ; PROSPERO:\n NCT05742802<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/bmjresp-2026-004145","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:25:14Z","timestamp":1784561114000},"page":"e004145","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05166889","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05158387","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06040086","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05742802","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05166889","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05158387","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06040086","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05742802","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05166889","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05158387","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06040086","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05742802","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Henrik","family":"Watz","sequence":"first","affiliation":[{"name":"Velocity Clinical Research Germany, Ahrensburg, Germany"},{"name":"Department of Pulmonary Medicine, University Hospital Schleswig-Holstein, Campus L\u00fcbeck, L\u00fcbeck, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Gro\u00dfhansdorf, SH, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7468-2225","authenticated-orcid":false,"given":"Frank C","family":"Sciurba","sequence":"additional","affiliation":[{"name":"Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bonini","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, Roma, Italy"},{"name":"National Heart and Lung Institute, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahi","family":"Ya\u00f1ez","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Allergy and Respiratory Disease, InAER, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bourdin","sequence":"additional","affiliation":[{"name":"PhyMedExp, University of Montpellier, CNRS, INSERM, CHU de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Zheng","sequence":"additional","affiliation":[{"name":"Guangzhou Institute of Respiratory Health, Guangzhou Medical College First Affiliated Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"De Soyza","sequence":"additional","affiliation":[{"name":"Respiratory Department, Population and Health Science Institute, Newcastle University, Newcastle upon Tyne, UK"},{"name":"Freeman Hospital, Sir William Leech Research Centre, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Janssens","sequence":"additional","affiliation":[{"name":"Respiratory Diseases, University Hospital Leuven & KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"van den Berge","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Fu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Tongji Hospital, Institute of Respiratory Medicine, School of Medicine, Tongji University, Shanghai, China"},{"name":"Department of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Luporini","family":"Saraiva","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Biometrics, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eulalia","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Lofdahl","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mikosz","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Kishishita","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Jackson","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Johnson","sequence":"additional","affiliation":[{"name":"Global Medical, Respiratory and Immunology BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Fager\u00e5s","sequence":"additional","affiliation":[{"name":"Global Medical, Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7284-0111","authenticated-orcid":false,"given":"Ioannis","family":"Psallidas","sequence":"additional","affiliation":[{"name":"Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2026072008250755000_13.1.e004145.1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2026072008250755000_13.1.e004145.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069679","article-title":"Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019","volume":"378","author":"Safiri","year":"2022","journal-title":"BMJ"},{"key":"2026072008250755000_13.1.e004145.3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-2600(21)00511-7","article-title":"Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis","volume":"10","author":"Adeloye","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026072008250755000_13.1.e004145.4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46598","article-title":"Global Burden of Chronic Obstructive Pulmonary Disease Through 2050","volume":"6","author":"Boers","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026072008250755000_13.1.e004145.5","doi-asserted-by":"publisher","DOI":"10.1111\/resp.14349"},{"key":"2026072008250755000_13.1.e004145.6","unstructured":"Our World in Data . Cancer death rate by type. Available: https:\/\/ourworldindata.org\/grapher\/cancer-death-rates-by-type?tab=table&time=1990..latest&showSelectionOnlyInTable=1 [Accessed 21 Mar 2025]."},{"key":"2026072008250755000_13.1.e004145.7","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-017-0548-3","article-title":"Understanding the impact of symptoms on the burden of COPD","volume":"18","author":"Miravitlles","year":"2017","journal-title":"Respir Res"},{"key":"2026072008250755000_13.1.e004145.8","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/COPD.S267002","article-title":"Defining chronic mucus hypersecretion Using the CAT in the SPIROMICS cohort","volume":"15","author":"Stott-Miller","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026072008250755000_13.1.e004145.9","doi-asserted-by":"crossref","first-page":"106921","DOI":"10.1016\/j.rmed.2022.106921","article-title":"Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and\/or COPD in the NOVELTY study","volume":"200","author":"Hughes","year":"2022","journal-title":"Respir Med"},{"key":"2026072008250755000_13.1.e004145.10","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2147\/COPD.S202580","article-title":"Impact of cough and mucus on COPD patients: primary insights from an exploratory study with an Online Patient Community","volume":"14","author":"Cook","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026072008250755000_13.1.e004145.11","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S38938"},{"key":"2026072008250755000_13.1.e004145.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.2065"},{"key":"2026072008250755000_13.1.e004145.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.12.046"},{"key":"2026072008250755000_13.1.e004145.14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200612-1772OC"},{"key":"2026072008250755000_13.1.e004145.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61382-8"},{"key":"2026072008250755000_13.1.e004145.16","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.10.847"},{"key":"2026072008250755000_13.1.e004145.17","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S438893"},{"key":"2026072008250755000_13.1.e004145.18","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s12325-024-02855-4","article-title":"Implications of cardiopulmonary risk for the management of COPD: a narrative review","volume":"41","author":"Singh","year":"2024","journal-title":"Adv Ther"},{"key":"2026072008250755000_13.1.e004145.19","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/COPD.S139470","article-title":"Impact and prevention of severe exacerbations of COPD: a review of the evidence","volume":"12","author":"Halpin","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026072008250755000_13.1.e004145.20","doi-asserted-by":"publisher","DOI":"10.3109\/15412555.2010.481697"},{"key":"2026072008250755000_13.1.e004145.21","unstructured":"Global initiative for chronic obstructive lung disease (GOLD) report. 2025. Available: https:\/\/goldcopd.org\/2025-gold-report\/ [Accessed 22 Jan 2025]."},{"key":"2026072008250755000_13.1.e004145.22","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.2147\/COPD.S172240","article-title":"Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?","volume":"13","author":"Tashkin","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026072008250755000_13.1.e004145.23","unstructured":"Nordon C , et al . Poster Presented at ERS Congress 2024. Vienna, Austria. Poster number: PA1287, 2024."},{"key":"2026072008250755000_13.1.e004145.24","doi-asserted-by":"crossref","first-page":"108743","DOI":"10.1016\/j.rmed.2026.108743","article-title":"BDP\/FF\/GB single-inhaler triple therapy in COPD: real-world effectiveness, safety, and adherence in a pooled analysis of 5,000 patients","volume":"254","author":"Brusselle","year":"2026","journal-title":"Respir Med"},{"key":"2026072008250755000_13.1.e004145.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k4388","article-title":"Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis","volume":"363","author":"Zheng","year":"2018","journal-title":"BMJ"},{"key":"2026072008250755000_13.1.e004145.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303951"},{"key":"2026072008250755000_13.1.e004145.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401304"},{"key":"2026072008250755000_13.1.e004145.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413181"},{"key":"2026072008250755000_13.1.e004145.29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2478\/jtim-2023-0096","article-title":"Blood eosinophils in chronic obstructive pulmonary disease: A potential biomarker","volume":"11","author":"Cui","year":"2023","journal-title":"J Transl Int Med"},{"key":"2026072008250755000_13.1.e004145.30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(17)30217-5","article-title":"Eosinophils in COPD: just another biomarker?","volume":"5","author":"Bafadhel","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026072008250755000_13.1.e004145.31","doi-asserted-by":"crossref","unstructured":"Cayrol C , Girard JP . Interleukin-33 (IL-33): A critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine. Cytokine 2022;156. doi:10.1016\/j.cyto.2022.155891","DOI":"10.1016\/j.cyto.2022.155891"},{"key":"2026072008250755000_13.1.e004145.32","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12552"},{"key":"2026072008250755000_13.1.e004145.33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-36642-y","article-title":"Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE\/EGFR to reduce inflammation and epithelial dysfunction","volume":"13","author":"England","year":"2023","journal-title":"Sci Rep"},{"key":"2026072008250755000_13.1.e004145.34","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02210-2022","article-title":"Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE\/EGFR signalling complex","volume":"62","author":"Strickson","year":"2023","journal-title":"Eur Respir J"},{"key":"2026072008250755000_13.1.e004145.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.mucimm.2023.07.002"},{"key":"2026072008250755000_13.1.e004145.36","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1146","article-title":"Interleukin (IL)-33: an orchestrator of immunity from host defence to tissue homeostasis","volume":"9","author":"Zhou","year":"2020","journal-title":"Clin Transl Immunology"},{"key":"2026072008250755000_13.1.e004145.37","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00305.2014"},{"key":"2026072008250755000_13.1.e004145.38","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1164\/rccm.202210-1881OC","article-title":"IL-33 expression Is lower in current smokers at both transcriptomic and protein levels","volume":"208","author":"Faiz","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026072008250755000_13.1.e004145.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.02.011"},{"key":"2026072008250755000_13.1.e004145.40","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00347-2024","article-title":"Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD","volume":"64","author":"Abdo","year":"2024","journal-title":"Eur Respir J"},{"key":"2026072008250755000_13.1.e004145.41","doi-asserted-by":"crossref","unstructured":"Strickson S , Scott IC , Collinson A , et al . Distinct pharmacological profiles of il-33 antibodies [poster]. Presented at American Thoracic Society 2024 International Conference 17-22 May 2024; San Diego, California, USA, 2024:A3294\u2013A94.","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A3294"},{"key":"2026072008250755000_13.1.e004145.42","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026072008250755000_13.1.e004145.43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial","volume":"10","author":"Yousuf","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026072008250755000_13.1.e004145.44","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2026.2639673","article-title":"Structures of clinical antibodies bound to IL-33 uncover two distinct epitopes underlying differential efficacy","volume":"18","author":"Chen","year":"2026","journal-title":"MAbs"},{"key":"2026072008250755000_13.1.e004145.45","doi-asserted-by":"crossref","unstructured":"Asrat S , Mao Y , Zhou Y , et al . Itepekimab binds to il-33 with high affinity, prevents the formation of il-33\/st2\/il-1racp signaling complex and blocks mediators of airway inflammation. American Thoracic Society 2023 International Conference; Washington, DC, 2023 Available: https:\/\/www.atsjournals.org\/doi\/book\/10.1164\/ajrccm-conference.2023.C13","DOI":"10.1164\/ajrccm-conference.2023.207.1_MeetingAbstracts.A4478"},{"key":"2026072008250755000_13.1.e004145.46","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A6895","article-title":"Structural basis for inhibition of IL-33 induced ST2 activation by astegolimab","volume":"211","author":"Ravala","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026072008250755000_13.1.e004145.47","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02231-2024"},{"key":"2026072008250755000_13.1.e004145.48","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/cpt.3147","article-title":"A randomized phase I study of the anti-Interleukin-33 antibody tozorakimab in healthy adults and patients with chronic obstructive pulmonary disease","volume":"115","author":"Reid","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"2026072008250755000_13.1.e004145.49","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00002610"},{"key":"2026072008250755000_13.1.e004145.50","article-title":"Management of chronic obstructive pulmonary disease (COPD) exacerbations in hospitalized patients from admission to discharge: a comprehensive review of therapeutic interventions","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2026-004145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:25:19Z","timestamp":1784561119000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2026-004145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,20]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjresp-2026-004145"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2026-004145","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}